Renal Testing: Three Markers, One Question, and What Each Cannot Answer

Quick Answer — All three renal markers answer the same narrow question: how well is the glomerulus filtering? None of them answers the questions that most change treatment — is there protein loss, can the kidney concentrate urine, is there infection or tubular damage? A renal workup that consists only of filtration markers is therefore incomplete by design, whatever the marker’s analytical quality.

Quick Answer

Markers disagree because they measure different things imperfectly. The disagreement is information, not noise.

The three markers

Marker	Strength	Limitation	Best use
Creatinine	Universal, well understood, cheap	Muscle-mass dependent; insensitive until substantial loss	Baseline and staging
SDMA	Less muscle-mass dependent	Not a damage marker; still confounded by hydration	Discordant cases; wasted or muscular patients
Cystatin C	Orthogonal to creatinine	Thinner veterinary evidence base; non-renal influences	Third opinion when the first two disagree

Reading the disagreement

Creatinine	SDMA	Likely explanation	Next step
High	High	Reduced filtration likely	Rehydrate, urinalysis, blood pressure
High	Normal	Muscle mass effect or prerenal azotaemia	Recheck after rehydration
Normal	High	Early filtration loss or muscle-wasting effect	Repeat both on one sample; assess proteinuria
Normal	Normal	Filtration likely preserved	Still check urine: protein, sediment, specific gravity

The third row is the clinically interesting one: it is where an early decline can first appear, and where repeating on a single sample matters more than adding a fourth marker.

What the markers do not tell you

Question	Marker that answers it
Is there protein loss?	Urine protein:creatinine ratio
Can the kidney concentrate?	Urine specific gravity
Is there infection or inflammation?	Urinalysis, sediment, culture
Is the damage tubular or glomerular?	Urinalysis, protein pattern, biopsy
Is blood pressure elevated?	Blood pressure measurement

A cat with a normal SDMA and a UPC of 3.0 has active disease and needs treatment, regardless of its filtration markers. This is the single most important sentence for anyone building a renal protocol.

Structuring the workup

1. Creatinine and urine specific gravity together. Neither alone separates prerenal from renal azotaemia.
2. SDMA where the creatinine picture is confounded — muscular breeds, severe muscle wasting, or a discrepancy with clinical signs.
3. UPC in every animal with suspected or confirmed renal disease, because proteinuria is both a staging variable and a treatment target.
4. Blood pressure, because hypertension both causes and results from renal injury.
5. Staging where chronic kidney disease is confirmed, using the current guideline framework.

Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.

Monitoring

For a stable patient, the useful monitoring set is creatinine or SDMA (consistently the same marker), UPC, blood pressure, body weight and clinical status. Changing markers mid-course produces a trend that cannot be interpreted; the same-analyzer principle applies across the whole panel, not just to one assay.

Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.

Gaps in the current menu, stated plainly

Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.

Six traps

1. Treating SDMA as a replacement for creatinine. They answer related but different questions.
2. Skipping urinalysis. The most consequential omission in renal workups.
3. Diagnosing renal disease in a dehydrated animal. Repeat after rehydration.
4. Ignoring muscle mass. Both directions: muscular dogs and wasted cats.
5. Comparing markers across platforms. Calibration differs.
6. Monitoring with different markers on different visits. Trend becomes uninterpretable.

The Author’s Take

Position. Renal is the category where a vendor should compete on the completeness of the workup, not on the sophistication of one marker.

Reasoning. The market conversation has been about which filtration marker is better, and that conversation has largely run its course — clinicians know that both creatinine and SDMA have limits. What remains unsolved is the practical one: most renal workups still skip UPC and blood pressure, which are the variables that actually change treatment. A vendor that publishes a workup sequence with a clear “these markers do not answer these questions” table is doing something more valuable than claiming superiority for its assay, and it positions the platform as the entry point to a complete assessment rather than a single-number screen.

Disclosure. Written from published veterinary nephrology guidance; no new experimental data. Values marked are placeholders for Migibio’s platform data.

Related pages

• Canine chronic kidney disease · Feline chronic kidney disease
• SDMA · Cystatin C

Sources

1. Reference to be added.
2. Reference to be added.
3. CLSI EP28-A3c — reference interval methodology.